Business
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter Industr
About this update from Entera Bio Ltd.
[{"type":"image","alt":"OPKO Health, Inc.","displaySize":"","headline":null,"caption":"OPKO Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/b17914b826278f91fa68691266a03f35"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2OiZoOrClmqtm95qDejWBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b17914b826278f91fa68691266a03f35","width":300,"height":300}},"lazy":false},{"type":"text","content":"This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities","length":147,"tagName":"p"},{"type":"text","content":"The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026","length":118,"tagName":"p"},{"type":"text","content":"Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter","length":230,"tagName":"p"},{"type":"text","content":"Industry veteran Steve Rubin joins Entera’s board","length":49,"tagName":"p"},{"type":"text","content":"MIAMI and TEL AVIV, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO), and Entera Bio Ltd. (NASDAQ: ENTX) (Entera or the Company), a leader in the development of oral peptide and protein replacement therapies, today announced the expansion of their 2025 Collaboration and License Agreement to advance the first oral long-acting PTH analog (LA-PTH) as a once-daily tablet for patients with hypoparathyroidism.","length":492,"tagName":"p"},{"type":"text","content":"The additional program combines OPKO's proprietary long-acting PTH variants with Entera's proprietary N-Tab® technology. Following favorable pharmacodynamic and pharmacokinetic (PK/PD) data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an IND application with the U.S. Food and Drug Administration (FDA) in late 2026.","length":386,"tagName":"p"},{"type":"text","content":"Under the expanded collaboration agreement, OPKO and Entera will each hold a 50% pro-ra...